Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Bone Marrow Transplantation

Volumn 51, Issue 1, 2016, Pages 58-66

  Klyuchnikov, E ^a   Bacher, U ^b   Woo Ahn, K ^c   Carreras, J ^c   Kroger N M ^a   Hari, P N ^c   Ku, G H ^d   Ayala, E ^e   Chen, A I ^f   Chen, Y B ^g   Cohen, J B ^h   Freytes, C O ⁱ   Gale, R P ^j   Kamble, R T ^k   Kharfan Dabaja, M A ^e   Lazarus, H M ^l   Martino, R ^m   Mussetti, A ^n,o   Savani, B N ^p   Schouten, H C ^q   Usmani, S Z ^r   Wiernik, P H ^s   Wirk, B ^t   Smith, S M ^u   Sureda, A ^v,w   Hamadani, M ^c   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k CENTER FOR CELL AND GENE THERAPY   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁿ NATIONAL CANCER INSTITUTE   (Italy)

^o UNIVERSITY OF MILAN   (Italy)

^p VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r LEVINE CANCER INSTITUTE   (United States)

^s OUR LADY OF MERCY MEDICAL CENTER   (United States)

^t SEATTLE CANCER CARE ALLIANCE   (United States)

^u UNIVERSITY OF CHICAGO   (United States)

^v HOSPITAL DURAN I REYNALS   (Spain)

^w European Group for Blood and Marrow Transplantation Lymphoma Working Party   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; MITOXANTRONE; RITUXIMAB; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; ALLOGRAFT; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SURVIVAL RATE; TIME FACTOR;

ADULT; AGED; ALLOGRAFTS; AUTOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS;

EID: 84953367337     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.223     Document Type: Article

References (38)

1. Nathwani BN, Harris NL, Weisenberger DD. Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008, pp 162-167.
2. Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, Trinh D et al. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol 2004; 121: 34-42.
3. Pruneri G, Valentini S, Fabris S, Del Curto B, Laszlo D, Bertolini F et al. Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1; q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. Int J Cancer 2004; 112: 71-77.
4. Guo Y, Karube K, Kawano R, Kawano R, Yamaguchi T, Suzumiya J et al. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia 2005; 19: 1058-1063.
5. Naresh KN. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 2007; 92: 267-268.
6. Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica 2011; 96: 1327-1334.
7. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
8. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
9. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB et al. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw 2014; 12: 916-946.
10. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii76-iii82.
11. Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N et al. Longterm follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21: 2324-2331.
12. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530-5536.
13. Pham RN, Gooley TA, Keeney GE, Press OW, Pagel JM, Greisman HA et al. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Bone Marrow Transplant 2007; 40: 1039-1044.
14. Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008; 14: 36-42.
15. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 2013; 19: 746-753.
16. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
17. Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008; 14: 748-758.
18. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011; 24: 203-216.
19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
20. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
21. Zhang X, Loberiza FR, Klein JP, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed 2007; 88: 95-101.
22. Zhang X, Zhang MJ. SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed 2011; 101: 87-93.
23. Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013; 48: 1409-1414.
24. Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 2012; 156: 225-233.
25. Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 2003; 89: 36-42.
26. Hsi ED, Mirza I, Lozanski G, Hill J, Pohlman B, Karafa MT et al. A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. Arch Pathol Lab Med 2004; 128: 863-868.
27. Hans CP, Weisenburger DD, Vose JM, Hock LM, Lynch JC, Aoun P et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363-2367.
28. Shustik J, Quinn M, Connors JM, Gascoyne RD, Skinnider B, Sehn LH. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 2011; 22: 1164-1169.
29. Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S et al. Role of non-myeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022-4031.
30. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003; 14: 737-744.
31. van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521-3529.
32. van Besien KW, de Lima M, Giralt SA, Moore DF Jr., Khouri IF, Rondon G et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977-982.
33. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 32: 1159-1163.
34. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667-2674.
35. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540-2544.
36. Gyan E, Foussard C, Bertrand P, Michenet P, le Gouill S, Berthou C et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009; 113: 995-1001.
37. Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24: 1119-1126.
38. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-1183.